We’ll see you in six months.
What is OCREVUS?
OCREVUS: Prescription medication for multiple sclerosis.
Multiple Sclerosis treatment with OCREVUS helps with the signs and symptoms of both Relapsing-Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS).
OCREVUS has shown promising results in:
• Reducing the frequency of RRMS relapses.
• Slowing the overall progression of RRMS and PPMS.
• Slowing the worsening of multiple sclerosis symptoms in both RRMS and PPMS.
OCREVUS also leaves you free to get on with life between MS treatments – after the first dose, you’ll only need to take it every six months.
Helpful Patient Resources
OCREVUS IV is PHARMAC funded for people with RRMS and PPMS who meet pre-defined criteria.
OCREVUS subcutaneous is registered and not PHARMAC funded.
If you would like more information please contact Roche Products (New Zealand) Ltd. on freephone 0800 656 464
OCREVUS is not suitable for everyone, so it is important that you discuss with your doctor or nurse whether this medicine is right for you.
Multiple Sclerosis Society of New Zealand
Multiple Sclerosis NZ is on a mission to coordinate and lead the advances in best practice multiple sclerosis care. They do this by providing national leadership, advocacy, information, education and raising awareness.
For more information and to contact your local Multiple Sclerosis support office, go to www.msnz.org.nz/contact-your-regional-society/